Brief: Vistagen Announces Results Of Successful US Phase 1 Study Of Itruvone, Enabling US Phase 2B Development For Treatment Of Major Depressive Disorder
21/06/2023 13:39
June 21 (Reuters) - Vistagen Therapeutics Inc VTGN.O :
* VISTAGEN ANNOUNCES RESULTS OF SUCCESSFUL U.S. PHASE 1
STUDY OF
ITRUVONE (PH10), ENABLING U.S. PHASE 2B DEVELOPMENT FOR
TREATMENT OF MAJOR DEPRESSIVE DISORDER
* VISTAGEN: ITRUVONE WAS WELL-TOLERATED, DEMONSTRATED
FAVORABLE
SAFETY & TOLERABILITY PROFILE ACROSS SINGLE AND MULTIPLE DOSE
INTRANASAL ADMINISTRATIONS
Source text for Eikon: ID:nBw5yzlh4a
Further company coverage: VTGN.O
(Reuters.Briefs@thomsonreuters.com)
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors